Entering text into the input field will update the search result below

Actinium Pharmaceuticals, Inc. (ATNM) Has The Technology, The Market, And The Connections

Jan. 23, 2014 3:10 PM ET
MissionIR profile picture
MissionIR's Blog
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Small cap

Seeking Alpha Analyst Since 2010

We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to building shareholder value. View our website at www.MissionIR.com MissionIR provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.missionir.com.

Actinium Pharmaceuticals, a New York based biopharmaceutical company specializing in the development of cancer drugs, has important connections in both research and industry, and is targeting a major market for which there is currently no approved drug.

In research, Actinium's patented technology was co-developed with Memorial Sloan Kettering Cancer Center (MSKCC), one of the world's most prestigious cancer centers. In addition, Actinium's largest shareholder, AHLB Holdings LLC, is wholly owned by MSKCC. In industry, the company's second largest shareholder is a subsidiary of Merck & Co., one of the largest pharmaceutical companies in the world.

Actinium is focused on treating cancer. Half of all men, and a third of all women, will develop at least one form of cancer during their lifetime. The U.S. alone registers 1.5 million new cancer cases annually, with over 12 million worldwide, and this doesn't include non-melanoma skin cancers. Worldwide sales of biopharmaceutical products for treating cancer are approximately $50 billion per year with U.S. sales being approximately half of that.

Actinium is currently developing blood cancer therapies, built on proprietary Alpha Particle Immunotherapy (OTC:APIT) technology. The company's primary drug candidate, Iomab-B, is for the treatment of acute myeloid leukemia, and is already prepared to enter a pivotal Phase III trial, which may lead to FDA approval. Iomab-B is developed for patients age 55 or older who suffer from acute myeloid leukemia, one of the deadliest of blood cancers for which there are no approved drugs. Another drug, Actimab-A, also for acute myeloid leukemia, is on track to produce Phase I/II interim data in 4Q 2014.

Actinium's market potential is further strengthened by the fact that its highly patented platform technology could be used to target a wide variety of cancers. Preclinical and clinical work has already focused on Non-Hodgkin Lymphoma (NHL), brain cancer, bladder cancer, ovarian cancer, breast cancer, prostate cancer, and a number of other cancer related indications. (Algeta, a company with similar technology, was recently bought by Bayer for $2.4 billion.)

For additional information, visit ActiniumPharmaceuticals.com

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.